SCHEMBL8683774

SCHEMBL8683774

COC(=O)c1ccc2c(CCCNc3ccccn3)nn(Cc3ccccc3)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC16A3 O15427 1/20 0.41
▸ SLC22A12 Q96S37 2/20 0.39
▸ ITGB3 P05106 5/20 0.39
▸ ITGAV P06756 5/20 0.39
▸ ITGB5 P18084 2/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ GAA P10253 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ITGB1 P05556 1/20 0.38
▸ ITGB6 P18564 1/20 0.38
▸ SCN8A Q9UQD0 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ F2RL3 Q96RI0 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8682759 0.86 ITGB3 (0.40) ITGB3ITGAVITGB5GAARAB9A
SCHEMBL8687237 0.79 SLC22A12 (0.44) SLC16A3SLC22A12MEN1KMT2AGAA
SCHEMBL4958032 0.78 CSNK2A2 (0.43) SLC22A12ITGB3ITGAVITGB5ITGB1
SCHEMBL8682285 0.76 SLC22A12 (0.44) SLC16A3SLC22A12MEN1KMT2AGAA
SCHEMBL1553851 0.75 SLC22A12 (0.58) SLC22A12MEN1KMT2AGAARAB9A
SCHEMBL14977876 0.70 F2RL3 (0.48) SLC16A3MEN1KMT2AGAARAB9A
SCHEMBL16127813 0.69 GAA (0.52) SLC22A12MEN1KMT2AGAARAB9A
SCHEMBL7030784 0.68 ITGB3 (0.52) ITGB3ITGAVITGB5ITGB1ITGB6
SCHEMBL7414619 0.67 SLC22A12 (0.46) SLC22A12MEN1KMT2AGAAKDM4E
SCHEMBL8682252 0.67 KDM4E (0.42) ITGB3ITGAVMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5760028-A TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-02 — — US disclosed
Send feedback